Outset Medical general counsel John Brottem sells $26,344 in stock

Published 2025-01-22, 06:06 p/m
OM
-

Earlier, on January 17, Brottem acquired 9,090 shares of common stock without any cost, as part of performance-based restricted stock units that vested upon the satisfaction of specific performance criteria. Following these transactions, Brottem holds 181,188 shares of Outset Medical (TASE:PMCN) directly. The company maintains a strong liquidity position with a current ratio of 6.49, indicating solid short-term financial health. For comprehensive insider trading analysis and 12 additional key insights about Outset Medical, visit InvestingPro. The company maintains a strong liquidity position with a current ratio of 6.49, indicating solid short-term financial health. For comprehensive insider trading analysis and 12 additional key insights about Outset Medical, visit InvestingPro.

Earlier, on January 17, Brottem acquired 9,090 shares of common stock without any cost, as part of performance-based restricted stock units that vested upon the satisfaction of specific performance criteria. Following these transactions, Brottem holds 181,188 shares of Outset Medical directly.

"In other recent news, Outset Medical, Inc. has reported robust Q3 2024 results, with revenue reaching $28.7 million, surpassing guidance. Treatment revenue was up by 14% and service revenue by 22%. Despite a net loss of $20.2 million, this was an improvement from the previous year, and the company's gross margin improved to 36.4%. The company also raised its 2024 revenue guidance to approximately $112 million.

Simultaneously, Outset Medical completed a private placement offering and issued Series A Non-Voting Convertible Preferred Stock. The company also borrowed $100 million as an initial term loan from Perceptive Credit Holdings IV, LP, and issued a warrant for the purchase of over 5 million shares of its common stock.

On the analyst front, BTIG analyst Maria Thibault revised the price target for Outset Medical to $3.00, a decrease from the previous $4.00, while maintaining a Buy rating for the stock. These are recent developments that investors should be aware of."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.